Jing Huang

Principal investigator of ESCORT, the trial that established camrelizumab in oesophageal squamous cell carcinoma.

Jing Huang led ESCORT and ESCORT-1st, the camrelizumab trials in advanced oesophageal squamous cell carcinoma, and studies of other PD-1 antibodies in oesophageal cancer.

Role

Professor of Medical Oncology; Cancer Hospital, Chinese Academy of Medical Sciences

Institution

Cancer Hospital, Chinese Academy of Medical Sciences

Specialisms

Oesophageal cancerImmunotherapyClinical trials

Profiles

Papers

1top

Title	Journal	Year
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT)	Lancet Oncology	2020

Connected

4top

Pages like this

not linked directly; found by shared links

Person
Rui-Hua Xu
Shares ESCORT-1st, Camrelizumab, Oesophageal cancer.
Person
Jie He
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Oesophageal cancer.
Collection
CSCO guidelines (China)
Shares Camrelizumab, Cancer Hospital, Chinese Academy of Medical Sciences, Oesophageal cancer.
Institution
Chinese Society of Clinical Oncology
Shares Cancer Hospital, Chinese Academy of Medical Sciences, Oesophageal cancer.

Jing Huang

Papers

Connected

Pages like this

cancers

drugs

institutions

trials